CSRIX
Price
$54.78
Change
-$0.10 (-0.18%)
Updated
Aug 21 closing price
Net Assets
9.23B
RYREX
Price
$44.16
Change
-$0.05 (-0.11%)
Updated
Aug 21 closing price
Net Assets
4.21M
Interact to see
Advertisement

CSRIX vs RYREX

CSRIX vs RYREX Comparison Chart in %
View a ticker or compare two or three
VS
CSRIX vs. RYREX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSRIX is a Hold and RYREX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CSRIX has more cash in the bank: 9.23B vs. RYREX (4.21M). RYREX pays higher dividends than CSRIX: RYREX (3.15) vs CSRIX (2.68). CSRIX was incepted earlier than RYREX: CSRIX (27 years) vs RYREX (22 years). RYREX (1.70) is less costly to investors than CSRIX (0.76). RYREX is a more actively managed with annual turnover of: 1408.00 vs. CSRIX (33.00). RYREX has a lower initial minimum investment than CSRIX: RYREX (2500) vs CSRIX (1000000). CSRIX annual gain was more profitable for investors over the last year : 15.19 vs. RYREX (11.97). CSRIX return over 5 years is better than : 15.94 vs. RYREX (6.51).
CSRIXRYREXCSRIX / RYREX
Total Expense Ratio0.751.6545%
Annual Report Gross Expense Ratio0.761.7045%
Fund Existence27 years22 years-
Gain YTD16.07711.571139%
Front LoadN/A5%-
Min. Initial Investment1000000250040,000%
Min. Initial Investment IRAN/AN/A-
Net Assets9.23B4.21M219,415%
Annual Yield % from dividends2.683.1585%
Returns for 1 year15.1911.97127%
Returns for 3 years41.4236.29114%
Returns for 5 years15.946.51245%
Returns for 10 years47.1944.28107%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GOIGX38.740.45
+1.18%
JHancock International Growth A
GQSIX19.900.20
+1.02%
Glenmede Disciplined U.S. Sm Cp Eq Instl
GATAX52.960.50
+0.95%
Gabelli Asset A
WFEIX65.330.49
+0.76%
Allspring Mid Cap Growth Fund - Cl Inst
AIGGX15.930.05
+0.31%
Aristotle Growth Equity I-2